Keyphrases
5-HT2A Receptor
9%
5-hydroxytryptamine
7%
Adverse Events
7%
Alzheimer's Disease
45%
Bipolar Disorder
11%
Calcitonin Gene-related Peptide
27%
Cerebral Blood Flow
13%
Cerebrospinal Fluid
25%
Cerebrospinal Fluid Biomarkers
7%
Chronic Migraine
10%
Clinical Practice
6%
Clinical Trials
10%
Cluster Headache
18%
Cognitive Function
7%
Cognitive Impairment
11%
Comorbidity
8%
Confidence Interval
23%
COVID-19
7%
Dementia
31%
Dementia Diagnosis
8%
Denmark
29%
Diabetic Nephropathy
6%
Diagnostic Criteria
8%
Disability
12%
Disease Activity
8%
Disease-modifying Therapy
10%
During Exercise
7%
Effectiveness Research
9%
Epilepsy
9%
Episodic Migraine
7%
Erenumab
8%
Europe
12%
Frontotemporal Dementia
12%
Functional Magnetic Resonance Imaging
14%
Genome-wide Association Study
8%
Global Burden of Disease Study
7%
Hazard Ratio
7%
Headache
56%
Healthy Controls
26%
Healthy Individuals
11%
Healthy Volunteers
12%
Hippocampus
8%
Huntington's Disease
10%
Idiopathic Intracranial Hypertension
10%
Induced Pluripotent Stem Cells (iPSCs)
7%
Interferon-β (IFN-β)
7%
Intracranial Pressure
7%
Ischemic Stroke
11%
Magnetic Resonance Imaging
15%
Major Depressive Disorder
12%
McArdle Disease
10%
Medication Overuse Headache
11%
Memory Clinic
9%
Meta-analysis
16%
Migraine
76%
Migraine Attack
18%
Migraine Patients
10%
Migraine Prevention
7%
Migraine Treatment
14%
Migraine without Aura (MWoA)
23%
Migraine-like
8%
Mild Alzheimer's Disease
6%
Mild Cognitive Impairment
11%
Multiple Sclerosis
100%
Multiple Sclerosis Treatment
18%
Myasthenia Gravis
7%
Natalizumab
8%
National Cohort Study
9%
Neurodegenerative Diseases
9%
Neurofilament Light (NF-L)
6%
Neurotrauma
9%
Non-associated
7%
Odds Ratio
12%
Optic Neuritis
9%
Pathophysiology
7%
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)
8%
Placebo
28%
Placebo-controlled
10%
Positron Emission Tomography
18%
Preventive Treatment
7%
Primary Headache
7%
Progressive multiple Sclerosis
10%
Quality of Life
8%
Radioligand
9%
Randomized Clinical Trial
7%
Randomized Controlled Trial
11%
Randomized Placebo-controlled Trial
7%
Receptor Binding
12%
Regional Cerebral Blood Flow (rCBF)
7%
Relapsing-remitting multiple Sclerosis
19%
Risk Factors
10%
Schizophrenia
6%
Serotonin 2A Receptor (5-HT2AR)
11%
Serotonin Transporter
8%
Single-photon Emission Computed Tomography (SPECT)
10%
Sumatriptan
8%
Systematic Meta-analysis
10%
Tension-type Headache
13%
Traumatic Brain Injury
20%
Triptans
6%
Medicine and Dentistry
Adverse Event
5%
Alzheimer's Disease
15%
Apoplexy
28%
Artery
7%
Atrial Fibrillation
5%
Auras
6%
Biological Marker
14%
Brain Blood Flow
11%
Brain Ischemia
11%
Calcitonin Gene Related Peptide
13%
Case-Control Study
6%
Cerebral Hemorrhage
5%
Cerebrospinal Fluid
10%
Clinical Trial
7%
Cluster Headache
9%
Cohort Analysis
14%
COVID-19
5%
Cross Sectional Study
5%
Diagnosis
23%
Disease
34%
Drug Therapy
11%
Epileptic Seizure
5%
Erenumab
5%
Exercise
6%
Global Disease Burden
7%
Glycogen Storage Disease Type V
9%
Headache
44%
Headache and Facial Pain
5%
Idiopathic Intracranial Hypertension
6%
Infusion
5%
Injury
6%
Intracranial Pressure
5%
Magnetic Resonance Imaging
26%
Medication Overuse Headache
7%
Meta-Analysis
10%
Migraine
57%
Migraine with Aura
7%
Migraine without Aura
5%
Multiple Sclerosis
42%
Muscle Strength
5%
Myopathy
8%
Nervous System Injury
7%
Neurologic Disease
5%
Neurology
5%
Observational Study
5%
Odds Ratio
6%
Pathophysiology
6%
Pediatrics
6%
Placebo
19%
Positron Emission Tomography
7%
Prevalence
13%
Prophylaxis
6%
Quality of Life
6%
Randomized Controlled Trial
8%
Symptom
24%
Systematic Review
19%
Tension Headache
10%
Transformed Migraine
5%
Traumatic Brain Injury
16%
Trigeminal Neuralgia
5%